NRD
KROS icon

Nebula Research & Development’s Keros Therapeutics KROS Stock Holding History

Nebula Research & Development’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90,406
Closed -$1.21M – 470
2025
Q2 		$1.21M Sell
90,406
-25,014
-22% -$338K 0.1% 334
2025
Q1 		$1.18M Buy
115,420
+43,710
+61% +$508K 0.11% 316
2024
Q4 		$1.14M Buy
71,710
+58,271
+434% +$3.03M 0.13% 255
2024
Q3 		$780K Buy
13,439
+5,185
+63% +$256K 0.09% 399
2024
Q2 		$377K Buy
+8,254
New +$444K 0.06% 519

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Nebula Research & Development's KROS Position: Q3 2025 in Review

Nebula Research & Development sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 90,406 shares — an estimated $1.21M sold.

Nebula Research & Development first reported a position in KROS in Q2 2024 and held it in 5 quarters. The position peaked at $1.21M in Q2 2025. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Nebula Research & Development reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 90,406 Keros Therapeutics shares in Q3 2025, an estimated $1.21M.
  • Nebula Research & Development first reported a position in Keros Therapeutics in Q2 2024 and held it in 5 quarters.
  • Nebula Research & Development's Keros Therapeutics position peaked at $1.21M in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.